ACR Payer Advocacy on Underwater Biosimilars
The ACR is engaging with payers regarding formulary requirements that would leave practices underwater when treating patients with rheumatic diseases.
Source: The Rheumatologist - Category: Rheumatology Authors: From the College Tags: Billing/Coding Legislation & Advocacy infliximab biosimilar Reimbursement Source Type: research